Mitrade Insights is dedicated to providing investors with rich, timely and most valuable financial information to help investors grasp the market situation and find timely trading opportunities.

2021

Best News & Analysis Provider

FxDailyInfo

2022

Best Forex Educational Resources Global

International Business Magazine

Insights

News

Cryptocurrencies

Morgan Stanley Names 3 Biotech Breakthroughs That Offer Investment Opportunities

Source Beincrypto

Morgan Stanley named three biotech breakthroughs that could reward investors, spanning Alzheimer’s drugs, gene editing, and artificial intelligence (AI).

Analysts Sean Laaman and Maxwell Skor published the research, and it coincided with the bank’s annual Global Healthcare Conference in New York.

Biotech Breakthroughs Carry Multibillion-Dollar Price Tags

Morgan Stanley’s report sizes the Alzheimer’s drug market at $70 billion. The bank splits it between therapies that slow cognitive decline and treatments for symptoms such as psychosis and agitation.

The bank sees upside beyond drugmakers. Delaying nursing home entry by 12 to 18 months could deliver US healthcare value worth multiples of list price. Diagnostics, care delivery, retirement, and insurance firms could also benefit or need to adapt.

Early gene-editing therapies worked ex vivo, meaning clinicians removed cells, edited them in a lab, and returned them. In contrast, in-vivo versions edit DNA inside the body. That could open organs not easily removed, including the brain, heart, eyes, and liver.

Pharma and Biotech performance has been climbing since mid-2025. Image Source: Janus Henderson

Morgan Stanley forecasts a $10 billion in-vivo market by 2035 in near-term indications. Meanwhile, consensus sits at $6 billion. Data due over the next 18 months could set how investors value these platforms.

Morgan Stanley Favors AI Suppliers Over Drug Developers

Analysts estimate AI could cut discovery timelines from about 4.5 years to 1.5 years. It could also lower research and development costs by 25% to 60%.

Yet there is little proof that AI raises the odds of a drug reaching patients. Therefore, the bank prefers the picks and shovels of AI, meaning firms supplying data, tools, and computing power.

Those businesses already convert adoption into revenue and rely less on binary clinical outcomes. The bank selectively monitors biotechs built around AI for clinical inflection points and treats large-cap productivity gains skeptically.

Trial Data and Oil Prices Could Test the Thesis

Clinical data can still swing biotech shares sharply, as Moderna’s August rally showed after a late-stage cancer vaccine result.

Timing also matters. Morgan Stanley strategist Mike Wilson warned in mid-September of a correction within 30 days if oil spikes drain liquidity.

The report suggests the most actionable exposure sits furthest from the lab, while the biggest upside awaits data.

Disclaimer: For information purposes only. Past performance is not indicative of future results.

Recommended Articles

October hike odds climb toward 60% as Goldman and BofA both flip — what Warsh's "dose of accommodation" really changed Rate futures now price roughly 55% to 62% for a 25bp hike at the October 27-28 FOMC, up from about 30% before Chair Warsh's post-meeting framing that the Fed is merely "removing some accommodation." Goldman Sachs has added an October hike to its forecast and Bank of America now sees moves in both October and December. Here is the repricing, the language behind it, and the two data points that decide it.

Author Irene Q.

Sep 23, Wed

Rate futures now price roughly 55% to 62% for a 25bp hike at the October 27-28 FOMC, up from about 30% before Chair Warsh's post-meeting framing that the Fed is merely "removing some accommodation." Goldman Sachs has added an October hike to its forecast and Bank of America now sees moves in both October and December. Here is the repricing, the language behind it, and the two data points that decide it.

Four jobs reports in five days: what JOLTS, ADP, claims and the September payrolls mean for the October Fed decision The US labour market faces its densest data week of the month. JOLTS job openings land Tuesday (7.2 million expected), ADP on Wednesday (70,000 expected), initial claims on Thursday and the September non-farm payrolls on Friday (100,000 expected, down from 162,000). Markets price a 64%-70% chance of another quarter-point Fed hike on October 28. The dollar index sits at 100.77 and the S&P 500 at 7,729.8.

Author Mitrade

Sep 28, Mon

The US labour market faces its densest data week of the month. JOLTS job openings land Tuesday (7.2 million expected), ADP on Wednesday (70,000 expected), initial claims on Thursday and the September non-farm payrolls on Friday (100,000 expected, down from 162,000). Markets price a 64%-70% chance of another quarter-point Fed hike on October 28. The dollar index sits at 100.77 and the S&P 500 at 7,729.8.

Nvidia's $150 billion buyback landed — and the AI sector fell anyway. That's the signal worth trading Nvidia closed up 1.68% at $228.86 on 28 September after announcing a $150 billion share repurchase authorisation, the largest single corporate buyback on record, while the rest of the AI complex sold off: AMD -3.6%, Micron -2.6%, Meta -4.8% and the Philadelphia Semiconductor Index -1.61%. The divergence is not noise. Capital is rotating toward cash-flow certainty, not abandoning the AI theme. With Micron reporting after the close on 30 September, here is what the split means.

Author Irene Q.

Sep 29, Tue

Nvidia closed up 1.68% at $228.86 on 28 September after announcing a $150 billion share repurchase authorisation, the largest single corporate buyback on record, while the rest of the AI complex sold off: AMD -3.6%, Micron -2.6%, Meta -4.8% and the Philadelphia Semiconductor Index -1.61%. The divergence is not noise. Capital is rotating toward cash-flow certainty, not abandoning the AI theme. With Micron reporting after the close on 30 September, here is what the split means.

【Daily Brief】30-year Treasury tops 5.59%, S&P 500 slips to 7,670 and gold holds $4,180 — PCE lands tonight The 30-year Treasury yield closed at 5.59%, its highest since June 2002, and the Dow fell 131.59 points to 51,349.92. US consumer confidence dropped to 81.9, a 12-year low, and JOLTS job openings fell to 7.1 million. August PCE and Q3 GDP both land at 8:30am ET tonight.

Author Suzie

Sep 30, Wed

The 30-year Treasury yield closed at 5.59%, its highest since June 2002, and the Dow fell 131.59 points to 51,349.92. US consumer confidence dropped to 81.9, a 12-year low, and JOLTS job openings fell to 7.1 million. August PCE and Q3 GDP both land at 8:30am ET tonight.

Gold falls to near $4,150 as higher Treasury yields, oil prices outweigh softer PCE inflation Gold price (XAU/USD) tumbles to near $4,150 during the early Asian session on Thursday, pressured by elevated US Treasury bond yields. Traders await the US September employment data for fresh impetus, which will be released later on Friday.

Author FXStreet

Yesterday 01: 26

Gold price (XAU/USD) tumbles to near $4,150 during the early Asian session on Thursday, pressured by elevated US Treasury bond yields. Traders await the US September employment data for fresh impetus, which will be released later on Friday.

Popular Symbols